Cyclosporine

New England Journal of Medicine

Volumn 321, Issue 25, 1989, Pages 1725-1738

  Oates, John A ^a   Wood, Alastair J j ^a   Kahan, Barry D ^b  

^a Department of Surgery ^*

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; CYCLOSPORIN DERIVATIVE;

BLOOD LEVEL; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; IMMUNOSUPPRESSIVE TREATMENT; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; HUMAN;

CYCLOSPORINS; HUMAN; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0024976004     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198912213212507     Document Type: Review

References (101)

1. Wenger RM. Cyclosporine: conformation and analogues as tools for studying its mechanism of action. Transplant Proc 1988; 20: Suppl 2: 313–8.
2. Kahan BD. Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters. Transplantation 1985; 40: 457–76.
3. Ellis CN, Gorsulowsky DC, Hamilton TA, et al. Cyclosporine improves psoriasis in a double-blind study. JAMA 1986; 256: 3110–6.
4. Bertault-Peres P, Bonfils C, Fabre G, Just S, Cano JP, Maurel P. Metabolism of cyclosporine A. II. Implication of the macrolide antibiotic inducible cytochrome P-450 3c from rabbit liver microsomes. Drug Metab Dispos 1987; 15: 391–8.
5. Maurer G, Loosli HR, Schreier E, Keiler B. Disposition of cyclosporine in several animal species and man. I. Structural elucidation of its metabolites. Drug Metab Dispos 1984; 12: 120–6.
6. Kahan BD, Grevel J. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 1988; 46: 631–44.
7. Ptachcinski RJ, Venkataramanan R, Burckart GJ. Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet 1986; 11: 107–32.
8. Ryffel B, Foxwell BM, Mihatsch MJ, Donatsch P, Maurer G. Biologic significance of cyclosporine metabolites. Transplant Proc 1988; 20: Suppl 2: 575–84.
9. Lindholm A, Henricsson S, Gang P. The free fraction of cyclosporine in plasma: clinical findings with a new method. Transplant Proc 1988; 20: Suppl 2: 377–81.
10. de Groen PC, Aksamit AJ, Rakela J, Forbes GS, Krom RAF. Central nervous system toxicity after liver transplantation: the role of cyclosporine and cholesterol. N Engl J Med 1987; 317: 861–6.
11. Yee GC, Kennedy MS, Storb R, Thomas ED. Effect of hepatic dysfunction on oral cyclosporin pharmacokinetics in marrow transplant patients. Blood 1984; 64: 1277–9.
12. Borel JF. Comparative study of in vitro and in vivo drug effects on cell-mediated cytotoxicity. Immunology 1976; 31: 631–41.
13. Hess AD, Tutschka PJ, Santos GW. Effect of cyclosporin A on human lymphocyte responses in vitro. III. CsA inhibits the production of T lymphocyte growth factors in secondary mixed lymphocyte responses but does not inhibit the response of primed lymphocytes to TCGF. J Immunol 1982; 128: 355–9.
14. Azogui O, Gluckman E, Fradelizi D. Inhibition of IL-2 production after human allogeneic bone marrow transplantation. J Immunol 1983; 131: 1205–8.
15. Yoshimura N, Kahan BD. Pharmacodynamic assessment of in vivo cyclosporine effect on interleukin-2 production by lymphocytes of kidney transplant recipients. Transplantation 1985; 40: 661–6.
16. LeGrue SJ, Friedman AW, Kahan BD. Binding of cyclosporine by human lymphocytes and phospholipid vesicles. J Immunol 1983; 131: 712–8.
17. Metcalfe S. Cyclosporine does not prevent cytoplasmic calcium changes associated with lymphocyte activation. Transplantation 1984; 38: 161–4.
18. Colombani PM, Robb A, Hess AD. Cyclosporine A binding to calmodulin: a possible site of action on T lymphocytes. Science 1985; 228: 337–9.
19. LeGrue SJ, Turner R, Weisbrodt N, Dedman JR. Does the binding of cyclosporine to calmodulin result in immunosuppression? Science 1986; 234: 68–71.
20. Citterio F, Kahan BD. The inhibitory effect of cyclosporine on the nuclear proliferative response to a variety of T cell activators. Transplantation 1989; 47: 334–8.
21. Harding MW, Handschumacher RE, Speicher DW. Isolation and amino acid sequence of cyclophilin. J Biol Chem 1986; 261: 8547–55.
22. Fischer G, Wittmann-Liebold B, Lang K, Kiefhaber T, Schmid FX. Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature 1989; 337: 476–8.
23. Burd PR, Rollins BJ, Wilson SD, Billings PR, Stiles CD, Dorf ME. Comparison of fibroblast and T-cell activation genes. Cell Immunol 1988; 115: 481–3.
24. Lee SW, Tsou A-P, Chan H, et al. Glucocorticoids selectively inhibit the transcription of the interleukin 1β gene and decrease the stability of interleukin 1β mRNA. Proc Natl Acad Sci U S A 1988; 85: 1204–8.
25. Kronke M, Leonard WJ, Depper JM, et al. Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sci U S A 1984; 81: 5214–8.
26. Elliott JF, Lin Y, Mizel SB, Bleackley RC, Harnish DG, Paetkau V. Induction of interleukin 2 messenger RNA inhibited by cyclosporin A. Science 1984; 226: 1439–41.
27. Granelli-Piperno A, Andrus L, Steinman RM. Lymphokine and nonlymphokine mRNA levels in stimulated human T cells. J Exp Med 1986; 163: 922–37.
28. Hess AD, Tutschka PJ. Effect of cyclosporin A on human lymphocyte responses in vitro. I. CsA allows for the expression of alloantigen-activated suppressor cells while preferentially inhibiting the induction of cytolytic effector lymphocytes in MLR. J Immunol 1980; 124: 2601–8.
29. Kupiec-Weglinski JW, Filho MA, Strom TB, Tilney NL. Sparing of suppressor cells: a critical action of cyclosporine. Transplantation 1984; 38: 97–101.
30. Beschorner WE, Olson JL, Hess AD, Di Gennaro KA, Santos GW. Cyclosporine-induced cell-mediated injury of the thymic medullary epithelium. Transplantation 1988; 45: 797–803.
31. Jenkins MK, Schwartz RH, Pardoll DM. Effects of cyclosporine A on T cell development and clonal deletion. Science 1988; 241: 1655–8.
32. O'Garra A, Warren DJ, Holman M, Popham A, Sanderson CJ, Klaus GG. Effects of cyclosporine on responses of murine B cells to T cell-derived lymphokines. J Immunol 1986; 137: 2220–4.
33. Esa AH, Paxman DG, Noga SJ, Hess AD. Sensitivity of monocyte subpopulations to cyclosporine: arachidonate metabolism and in vitro antigen presentation. Transplant Proc 1988; 20: Suppl 2: 80–6.
34. Granelli-Piperno A, Keane M. Effects of cyclosporine on T lymphocytes and accessory cells from human blood. Transplant Proc 1988; 20: Suppl 2: 136–42.
35. The Canadian Multicentre Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation: analysis at three years. N Engl J Med 1986; 314: 1219–25.
36. Kahan BD, van Buren CT, Flechner SM, et al. Clinical and experimental studies with cyclosporine in renal transplantation. Surgery 1985; 97: 125–40.
37. Najarian JS, Fryd DS, Strand M, et al. A single institution, randomized, prospective trial of cyclosporin versus azathioprine antilymphocyte globulin for immunosuppression in renal allograft recipients. Ann Surg 1985; 201: 142–57.
38. Showstack J, Katz P, Amend W, et al. The effect of cyclosporine on the use of hospital resources for kidney transplantation. N Engl J Med 1989; 321: 1086–92.
39. Oyer PE, Stinson EB, Jamieson SW, et al. Cyclosporine in cardiac transplantation: a 2 1/2 year follow-up. Transplant Proc 1983; 15: Suppl 1: 2546–52.
40. Starzl TE, Klintmalm GBG, Porter KA, Iwatsuki S, Schröter GPJ. Liver transplantation with use of cyclosporin A and prednisone. N Engl J Med 1981; 305: 266–9.
41. Reitz BA, Wallwork JL, Hunt SA, et al. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med 1982; 306: 557–64.
42. The Toronto Lung Transplant Group. Experience with single-lung transplantation for pulmonary fibrosis. JAMA 1988; 259: 2258–62.
43. Deeg HJ, Storb R, Thomas ED, et al. Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Blood 1985; 65: 1325–34.
44. Nussenblatt RB, Palestine AG, Chan CC. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol 1983; 96: 275–82.
45. Feutren G, Papoz L, Assan R, et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset: results of a multicentre double-blind trial. Lancet 1986; 2: 119–24.
46. Bougneres PF, Carel JC, Castano L, et al. Factors associated with early remission of Type I diabetes in children treated with cyclosporine. N Engl J Med 1988; 318: 663–70.
47. Tejani A, Butt K, Khawar MR, et al. Cyclosporine (CY) induced remission of relapsing nephrotic syndrome (RNS) in children. Kidney Int 1986; 29: 206. abstract.
48. Orre O, Bjerkhoel F, Salvesen CF, et al. An open, controlled, randomized comparison of cyclosporine and azathioprine in the treatment of rheumatoid arthritis: a preliminary report. Arthritis Rheum 1987; 30: 88–92.
49. Chappell LH, Thomson AW. Studies on the action of cyclosporine A against Schistosoma mansoni and other parasitic infections. Transplant Proc 1988; 20: Suppl 2: 291–7.
50. Drath DB, Kahan BD. Phagocytic cell function in response to immunosuppressive therapy. Arch Surg 1984; 119: 156–60.
51. Penn I. Cancers following cyclosporine therapy. Transplantation 1987; 43: 32–5.
52. Pickrell MD, Sawers R, Michael J. Pregnancy after renal transplantation: severe intrauterine growth retardation during treatment with cyclosporin A. Br Med J 1988; 296: 825.
53. Kahan BD, Flechner SM, Lorber MI, Golden D, Conley S, Van Buren CT. Complications of cyclosporine-prednisone immunosuppression in 402 renal allograft recipients exclusively followed at a single center for from one to five years. Transplantation 1987; 43: 197–204.
54. Bencini PL, Montagnino G, Sala F, De Vecchi A, Crosti C, Tarrantino A. Cutaneous lesions in 67 cyclosporin-treated renal transplant recipients. Dermatologica 1986; 172: 24–30.
55. Reznik VM, Jones KL, Durham BL, Mendoza SA. Changes in facial appearance during cyclosporin treatment. Lancet 1987; 1: 1405–7.
56. Wysocki GP, Gretzinger HA, Laupacis A, Ulan RA, Stiller CR. Fibrous hyperplasia of the gingiva: a side effect of cyclosporin A therapy. Oral Surg Oral Med Oral Pathol 1983; 55: 274–8.
57. Gunnarsson R, Klintmalm G, Lundgren G, et al. Deterioration in glucose metabolism in pancreatic transplant recipients after conversion from azathioprine to cyclosporine. Transplant Proc 1984; 16: 709–12.
58. Betschart JM, Virji MA, ShinozukaH. Cyclosporine A-induced alterations in rat hepatic glycogen metabolism. Transplant Proc 1988; 20: Suppl 3: 880–4.
59. Rajfer J, Sikka SC, Lemmi C, Koyle MA. Cyclosporine inhibits testosterone biosynthesis in the rat testis. Endocrinology 1987; 121: 586–9.
60. Movsowitz C, Epstein S, Fallon M, Insmail F, Thomas S. Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology 1988; 123: 2571–7.
61. Vanrenterghem Y, Roels L, Lerut T, et al. Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients. Lancet 1985; 1: 999–1002.
62. Grace AA, Barradas MA, Mikhailidis DP, et al. Cyclosporine A enhances platelet aggregation. Kidney Int 1987; 32: 889–95.
63. Carlesen E, Prydz H. Enhancement of procoagulant activity in stimulated mononuclear blood cells and monocytes by cyclosporine. Transplantation 1987; 43: 543–8.
64. Voss BL, Hamilton KK, Samara EN, McKee PA. Cyclosporine suppression of endothelial prostacyclin generation: a possible mechanism for nephrotoxicity. Transplantation 1988; 45: 793–6.
65. Shulman H, Striker G, Deeg HJ, Kennedy M, Storb R, Thomas ED. Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation: glomerular thromboses and tubular injury. N Engl J Med 1981; 305: 1392–5.
66. Van Buren D, Van Buren CT. Flechner SM, Maddox AM, Verani R, Kahan BD. De novo hemolytic uremic syndrome in renal transplant recipients immunosuppressed with cyclosporine. Surgery 1985; 98: 54–62.
67. Sawaya B, Provenzano R, Kupin WL, Venkat KK. Cyclosporine-induced renal macroangiopathy. Am J Kidney Dis 1988; 12: 534–7.
68. Tegzess AM, Doorenbos BM, Minderhound JM, Donker AJ. Prospective serial renal function studies in patients with nonrenal disease treated with cyclosporine A. Transplant Proc 1988; 20: Suppl 2: 390–3.
69. Palestine AG, Nussenblatt RB, Chan CC. Side effects of systemic cyclosporine in patients not undergoing transplantation. Am J Med 1984; 77: 652–6.
70. English J, Evan A, Houghton DC, Bennett WM. Cyclosporine-induced acute renal dysfunction in the rat: evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 1987; 44: 135–41.
71. Barros EJ, Boim MA, Ajzen H, Ramos OL, Schor N. Glomerular hemodynamics and hormonal participation in cyclosporine nephrotoxicity. Kidney Int 1987; 32: 19–25.
72. Murray BM, Palier MS, Ferris TF. Effect of cyclosporine administration on renal hemodynamics in conscious rats. Kidney Int 1985; 28: 767–74.
73. Curtis JJ, Luke RG, Dubovsky E, Diethelm AG, Whelchel JD, Jones P. Cyclosporin in therapeutic doses increases renal allograft vascular resistance. Lancet 1986; 2: 477–9.
74. Goldberg HJ, Wong PY, Cole EH, Levy GA, Skorecki KL. Dissociation between the immunosuppressive activity of cyclosporine derivatives and their effects on intracellular calcium signaling in mesangial cells. Transplantation 1989; 47: 731–3.
75. Coffman TM, Carr DR, Yarger WE, Klotman PE. Evidence that renal prostaglandin and thromboxane production is stimulated in chronic cyclosporine nephrotoxicity. Transplantation 1987; 43: 282–5.
76. Spragg J, Weinblatt ME, Coblyn J, Fraser P, Austen KF. Effect of cyclosporine on urinary kallikrein excretion in patients with rheumatoid arthritis. J Lab Clin Med 1988; 112: 324–32.
77. Weinberg JM. Issues in the pathophysiology of nephrotoxic renal tubular cell injury pertinent to understanding cyclosporine nephrotoxicity. Transplant Proc 1985; 17: Suppl 1: 81–90.
78. Mihatsch MJ. Thiel G, Ryffel B. Histopathology of cyclosporine nephrotoxicity. Transplant Proc 1988; 20: Suppl 3: 759–71.
79. Wagner K, Albrecht S, Neumayer HH. Prevention of posttransplant acute tubular necrosis by the calcium antagonist diltiazem: a prospective randomized study. Am J Nephrol 1987; 7: 287–91.
80. Lewis RM, Janney RP, Golden DL, et al. Stability of renal allograft function associated with long-term cyclosporine immunosuppressive therapy — five year follow-up. Transplantation 1989; 47: 266–72.
81. Myers BD, Sibley R, Newton L, et al. The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 1988; 33: 590–600.
82. Simmons RL, Canafax DM, Strand M, et al. Management and prevention of cyclosporine nephrotoxicity after renal transplantation: use of low doses of cyclosporine, azathioprine, and prednisone. Transplant Proc 1985; 17: Suppl 1: 266–75.
83. Ball PE, Munzer H, Keller HP, Abisch E, Rosenthaler J. Specific 3H radioimmunoassay with a monoclonal antibody for monitoring cyclosporine in blood. Clin Chem 1988; 34: 257–60.
84. Yee GC, Self SG, McGuire TR, Carlin J, Sanders JE, Deeg HJ. Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic bone marrow transplantation. N Engl J Med 1988; 319: 65–70.
85. Kahan BD, Wideman CA. Reid M, et al. The value of serial serum trough cyclosporine levels in human renal transplantation. Transplant Proc 1984; 16: 1195–9.
86. Rogerson ME, Marsden JT, Reid KE, Bewick M, Holt DW. Cyclosporine blood concentrations in the management of renal transplant recipients. Transplantation 1986; 41: 276–8.
87. Hiestand PC, Gunn HC, Gale JM, Ryffel B, Borel JF. Comparison of the pharmacological profiles of cyclosporine, (Nva2)-cyclosporine and (Val2) dihydro-cyclosporine. Immunology 1985; 55: 249–55.
88. Elzinga L, Kelley VE, Houghton DC, Bennett WM. Modification of experimental nephrotoxicity with fish oil as the vehicle for cyclosporine. Transplantation 1987; 43: 271–4.
89. Kelley VE, Kirkman RL, Bastos M, Barrett LV, Strom TB. Enhancement of immunosuppression by substitution of fish oil for olive oil as a vehicle for cyclosporine. Transplantation 1989; 48: 98–102.
90. Calne RY, White DJ, Thiru S, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1978; 2: 1323–7.
91. Salaman J. Cyclosporine mono-drug therapy. Transplant Proc 1988; 20: Suppl 3: 117–20.
92. Starzl TE, Weil R III, Iwatsuki S, et al. The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet 1980; 151: 17–26.
93. Santos GW, Tutschka PJ, Brookmeyer R, et al. Cyclosporine plus methylprednisolone versus cyclophosphamide plus methylprednisolone as prophylaxis for graft-versus-host disease: a randomized, double-blind study in patients undergoing allogeneic marrow transplantation. Clin Transplant 1987; 1: 21.
94. Wilkinson AH, Smith JL, Hunsicker LG, et al. Increased frequency of posttransplant lymphomas in patients treated with cyclosporin, azathioprine, and prednisone. Transplantation 1989; 47: 293–6.
95. Vathsala A, Chou T-C, Kahan BD. Analysis of the interactions of immunosuppressive drugs with cyclosporine to inhibit DNA proliferation. Transplantation (in press).
96. Palier MS. Effects of the prostaglandin E1 analog misoprostol on cyclosporine nephrotoxicity. Transplantation 1988; 45: 1126–31.
97. Weir MR, Peppier R, Gomolka D, Handwerger BS. Additive effect of cyclosporine and verapamil on the inhibition of activation and function of human peripheral blood mononuclear cells. Transplant Proc 1988; 20: Suppl 2: 240–4.
98. Didlake RH, Dreyfus K, Kerman RH, Van Buren CT, Kahan BD. Patient noncompliance: a major cause of later graft failure in cyclosporine-treated renal transplants. Transplant Proc 1988; 20: Suppl 3: 63–9.
99. Kupiec-Weglinski JW, Hahn HJ, Kirkman RL, et al. Cyclosporine potentiates the immunosuppressive effects of anti-interleukin 2 receptor monoclonal antibody therapy. Transplant Proc 1988; 20: Suppl 2: 207–16.
100. Yasumura T, Kahan BD. Prolongation of allograft survival by repeated cycles of donor antigen and cyclosporine in rat kidney transplantation. Transplantation 1984; 38: 418–23.
101. Knechtle SJ, Halperin EC, Bollinger RR. Xenograft survival in two species combinations using total-lymphoid irradiation and cyclosporine. Transplantation 1987; 43: 173–5.